JP2021505172A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505172A5
JP2021505172A5 JP2020531468A JP2020531468A JP2021505172A5 JP 2021505172 A5 JP2021505172 A5 JP 2021505172A5 JP 2020531468 A JP2020531468 A JP 2020531468A JP 2020531468 A JP2020531468 A JP 2020531468A JP 2021505172 A5 JP2021505172 A5 JP 2021505172A5
Authority
JP
Japan
Prior art keywords
donor
disease
cells
population
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020531468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505172A (ja
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Application filed filed Critical
Priority claimed from PCT/US2018/064335 external-priority patent/WO2019113375A2/en
Publication of JP2021505172A publication Critical patent/JP2021505172A/ja
Publication of JP2021505172A5 publication Critical patent/JP2021505172A5/ja
Priority to JP2023188499A priority Critical patent/JP2024023226A/ja
Pending legal-status Critical Current

Links

JP2020531468A 2017-12-06 2018-12-06 造血幹細胞及び前駆細胞を動員させるための投薬レジメン Pending JP2021505172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023188499A JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US15/834,017 2017-12-06
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 2018-08-13
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30
PCT/US2018/064335 WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188499A Division JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Publications (2)

Publication Number Publication Date
JP2021505172A JP2021505172A (ja) 2021-02-18
JP2021505172A5 true JP2021505172A5 (https=) 2022-01-11

Family

ID=66749948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531468A Pending JP2021505172A (ja) 2017-12-06 2018-12-06 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
JP2023188499A Pending JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023188499A Pending JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Country Status (12)

Country Link
EP (1) EP3720494A2 (https=)
JP (2) JP2021505172A (https=)
KR (1) KR20200096942A (https=)
CN (1) CN111712262A (https=)
AU (1) AU2018378804B2 (https=)
BR (1) BR112020011186A2 (https=)
CA (1) CA3083783A1 (https=)
CO (1) CO2020007275A2 (https=)
IL (2) IL275077B2 (https=)
MX (2) MX2020005878A (https=)
SG (1) SG11202004913TA (https=)
WO (1) WO2019113375A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20220401481A1 (en) * 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3176979A1 (en) * 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN119562815A (zh) * 2022-06-10 2025-03-04 Gpcr治疗公司 Gpcr抑制剂及其用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69433301T2 (de) 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
HU226994B1 (en) 1997-02-11 2010-04-28 Mallinckrodt Reactor and method for solid phase peptide synthesis
EP1068357B2 (en) 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
BR0010655A (pt) 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
DE60042030D1 (de) 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
CA2456977C (en) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
RU2008102646A (ru) 2005-06-24 2009-07-27 Риджентс Оф Дзе Юниверсити Оф Миннесота (Us) Применение цитозиндезаминаз для уменьшения переноса ретроэлементов от свиней человеку
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (en) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Solid phase peptide synthesis of peptide alcohols
BR112012020257A8 (pt) 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
BR112013021785A8 (pt) 2011-02-25 2018-07-03 Recombinetics Inc animais geneticamente modificados e métodos para fazer os mesmos
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20150366914A1 (en) * 2013-01-15 2015-12-24 Ohio State Innovation Foundation Methods for Mobilizing Hematopoietic Stem Cells
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Similar Documents

Publication Publication Date Title
JP2021505172A5 (https=)
Jurewicz et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes
Leyendecker Jr et al. The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review
US8685728B2 (en) Kit containing stem cells and cytokines for use in attenuating immune responses
Lu et al. Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia
Chang et al. Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation
Bacigalupo Alternative donor transplants for severe aplastic anemia
Hong et al. Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients
Luo et al. CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update
Picardi et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
Murphy et al. Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation
JP2021502824A5 (https=)
Ringdén et al. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease
Sodani et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
Gong et al. Alternative transplantation with post-transplantation cyclophosphamide in aplastic anemia: a retrospective report from the BMF-WG of Hunan Province, China
Fu et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic anemia
Fu et al. Recombinant human thrombopoietin promotes platelet engraftment in severe aplastic anemia patients following treatment with haploid hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide
Wu et al. Prospective study of a modified post-transplantation cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation
Lin et al. Role of memory T cells and perspectives for intervention in organ transplantation
Leung et al. Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies
Liang et al. Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy
Looi et al. Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies
Yolcu et al. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease
Dong et al. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin
Mahadeo et al. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor